Don Rowe, MD
Cardiovascular Disease · Snellville, GANPI 1245417666
Payments from drug & device makers
Across 175 payments — averaging $177.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$26K
- Cvrx, Inc.$561
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$555
- Medtronic$540
- Novo Nordisk$535
- Merck$347
- plus $3K from 31 others
What the payments were for
- Speaking & faculty fees$24,91080%
- Food & beverage$6,03119%
- Education$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 29 | $25,533 |
| Cvrx, Inc. | 3 | $561 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $555 |
| Medtronic(2 entities) | 4 | $540 |
| Novo Nordisk | 18 | $535 |
| Merck | 16 | $347 |
| Boston Scientific | 4 | $285 |
| Acarix USA Inc. | 2 | $275 |
| Abbott | 4 | $241 |
| AstraZeneca | 8 | $240 |
| E.r. Squibb & Sons, L.L.C. | 9 | $233 |
| Edwards Lifesciences | 4 | $230 |
| Boehringer Ingelheim | 10 | $204 |
| Impulse Dynamics (USA) Inc. | 3 | $158 |
| Stryker | 1 | $141 |
| Kestra Medical Technology Services, Inc. | 6 | $102 |
| Heartflow, Inc. | 1 | $97 |
| Johnson & Johnson | 5 | $94 |
| Novartis | 4 | $86 |
| Shockwave Medical, Inc | 2 | $80 |
| Daiichi Sankyo Inc. | 4 | $79 |
| Abiomed | 2 | $79 |
| Amgen | 3 | $48 |
| Cordis US CORP. | 2 | $41 |
| Lilly USA, LLC | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $35 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $29 |
| Cardiva Medical, Inc. | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Vivus LLC | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$25,033
- Barostim Neo System$561
- Micra$389
- ELIQUIS$364
- OPTIMIZER$248
- MitraClip System$182
- CADScor System$181
- SAPIEN 3 Ultra RESILIA$151
- AVVIGO Guidance System$147
- FLOWTRIEVER CATHETER, S$141
- CT THROMBECTOMY SYSTEM KIT$141
- SYMPLICITY G3$132
- FARXIGA$119
- Ozempic$116
- Wegovy$110
- LifeVest$110
How this compares
$31,060 in reported general payments places this provider in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 269 | $307,921 |
| JardianceEmpagliflozin | 52 | $66,791 |
| XareltoRivaroxaban | 74 | $55,667 |
| MounjaroTirzepatide | 17 | $36,004 |
| EntrestoSacubitril/Valsartan | 35 | $31,555 |
| OzempicSemaglutide | 21 | $27,068 |
| WegovySemaglutide | 13 | $17,581 |
| BrilintaTicagrelor | 16 | $11,998 |
| Sildenafil Citrate | 15 | $7,321 |
| Nebivolol Hcl | 101 | $5,174 |
| Ranolazine ErRanolazine | 30 | $3,033 |
| Atorvastatin Calcium | 244 | $2,043 |
| Metoprolol Succinate | 176 | $1,612 |
| Losartan Potassium | 123 | $1,431 |
| Amlodipine Besylate | 294 | $1,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $25,533 | $307,921269 claims |
| Boehringer IngelheimJardiance | $204 | $66,79152 claims |
| Johnson & JohnsonXarelto | $94 | $55,66774 claims |
| Novo NordiskOzempic, Wegovy | $535 | $44,64934 claims |
| Lilly USA, LLCMounjaro | $40 | $36,00417 claims |
| NovartisEntresto | $86 | $31,55535 claims |
| AstraZenecaBrilinta | $240 | $11,99816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Snellville
- Narendra SinghJohns Creek$5.4M
- Elizabeth OfiliAtlanta$4.5M
- Sanjay YadavAtlanta$3.7M
- Arshed QuyyumiAtlanta$3.4M
- Naresh ParikhNorcross$2.8M
- Nicolas ChronosEatonton$2.4M
- Bobby KhanAtlanta$1.7M
- Hunter ChampionColumbus$1.5M
- David SuhTucker$1.1M
- Michael MorrisAtlanta$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.